Hansa Biopharma — Oktober 2025
-
Og stiger næsten 9%.. svært at lure… på den ene side, så sikres kapital til forretningen, så potentialet fuldt kan udnyttes, uden vi andre igen og igen skal smide penge på bordet, på den anden side, så Kender vi ikke prisen og dermed udtyndingen.. ikke så nemt at lure..
-
Hansa Biopharma has carried out a directed share issue of 17 million shares, raising proceeds of approximately USD 71 million
-
The Board of Directors of Hansa has resolved on the Directed Share Issue at a subscription price of SEK 39.50 per share which was established through the accelerated book-building procedure carried out by the Joint Bookrunners and corresponds to a discount of approximately 7.6 percent in relation to the closing price on Nasdaq Stockholm on October 1, 2025 (SEK 42.74)
-
.. and approximately 0.3 percent in relation to the volume weighted average price during the last five trading days (approximately SEK 39.64). As a result of the large interest and demand in the accelerated book-building procedure, the Company decided to upsize the Directed Share Issue with approximately SEK 100 million in relation to what was communicated in the earlier press release.
-
.. The investors in the Directed Share Issue consisted of a number of Swedish and international institutional investors and the Company is pleased by the strong support it has received from new shareholders such as Polar Capital LLP, alongside existing shareholder Redmile Group, LLC, amongst others.
-
Når alt kommer til alt var det nok fint at få den emmission fyret af, selvom udvandingen på 16,7 er i den høje ende. Men vi får antageligt nogle professionelle langsigtede investorer med. Mon ikke kursen begynder at stige igen når inden så længe. Vi går et spændende efterår i møde.
-
Hansa har leveret: Idefirix godkendt i USA og Europa, teknologien fungerer. Men aktien er faldet 85% - det er fakta.
Ved kurs 49 priser markedet næsten fiasko ind. For langsigtede investorer (nogle/os) med 3-5 års horisont og stærke nerver kan niveauet være attraktivt. Spørgsmålet er ikke om, men hvornår
-
Ja, det giver jo lidt sig selv… men pointen er jo som med så mange andre Bio, evnen til at komme over disken. Det tager jo år at få overbevist systemer og læger om fortræffelighederne ved nye behandlingsmuligheder.. den 1/3 af mine biotek, der gennem tiden er hel fejlet undtaget, så har de andre været succesfulde med klare fordele, helbredsmæssigt og økonomisk! Men de er stadig langt fra at komme nogen vegne kommercielt.. det glemmer de fleste, når de banker kursen op efter et succesrigt studie.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind